KCNG1: A Potential Drug Target and Biomarker (G3755)

Target Name: KCNG1

NCBI ID: G3755

KCNG1

KCNG1: A Potential Drug Target and Biomarker

KCNG1, short for ketorcatenin1, is a gene that encodes a protein located in the endoplasmic reticulum (ER) of eukaryotic cells. ER is a network of organelles responsible for the synthesis, processing, and storage of proteins. The ER is also the site of modification and degradation of proteins, making it an attractive target for drugs with various mechanisms of action.

KCNG1, as a gene, has the potential to be a drug target due to its involvement in the ER and protein synthesis. Many drugs work by modulating the activity of proteins, either increasing or decreasing their activity. By targeting KCNG1, drugs can either activate or inhibit its function, leading to therapeutic effects. Additionally, as a gene, KCNG1 can also serve as a biomarker, providing a genetic basis for diseases or drug responses.

The ER is a complex organelle that forms the boundary between the cytoplasm and the nucleus. It is responsible for the synthesis, processing, and storage of proteins, as well as the modification and degradation of these proteins. The ER is composed of a network of interconnected structures, including the endoplasmic reticulum gap (ER fold), which is the boundary between the ER and the cytoplasm.

KCNG1 is a protein that is expressed in a variety of cell types, including muscle, nerve, and heart cells. It is localized to the ER and is involved in the ER-to-cytoplasm transport of proteins. This means that when a protein is synthesized in the ER, it is transported to the cytoplasm for further processing and storage.

In recent years, the study of the ER and its associated proteins has gained significant attention due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The ER is thought to play a crucial role in the regulation of protein synthesis , storage, and degradation, and alterations in its structure or function can have a significant impact on cellular processes.

KCNG1 is a gene that has been implicated in the regulation of protein synthesis in the ER. It encodes a protein that is involved in the ER-to-cytoplasm transport of proteins. This protein is composed of 120 amino acids and has a calculated molecular mass of 13.9 kDa. It is localized to the ER and is involved in the regulation of protein synthesis and storage in the ER.

The functions of KCNG1 are still being explored, but it is known to play a role in the regulation of protein synthesis and storage in the ER. Additionally, it is possible that KCNG1 may be a drug target due to its involvement in the ER and protein synthesis.

In conclusion, KCNG1 is a gene that encodes a protein located in the ER of eukaryotic cells. It is involved in the ER-to-cytoplasm transport of proteins and is thought to play a role in the regulation of protein synthesis and storage in the ER . Further research is needed to fully understand the functions of KCNG1 and its potential as a drug target.

Protein Name: Potassium Voltage-gated Channel Modifier Subfamily G Member 1

Functions: Potassium channel subunit that does not form functional channels by itself. Can form functional heterotetrameric channels with KCNB1; modulates the delayed rectifier voltage-gated potassium channel activation and deactivation rates of KCNB1 (PubMed:19074135)

The "KCNG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets